Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia
Abstract Case Approximately 3%‐25% of cases of endometrial carcinoma (EC) or atypical endometrial hyperplasia (AH) occur in women aged <40 years and conservative treatment with high‐dose medroxyprogesterone acetate (MPA) is administered to women who wish to preserve their fertility. Here is repor...
Main Authors: | Toshiya Matsuzaki, Takeshi Iwasa, Takako Kawakita, Yuri Yamamoto, Akiko Abe, Aki Hayashi, Kiyohito Yano, Masato Nishimura, Akira Kuwahara, Minoru Irahara |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado: |
Wiley
2018-07-01
|
Series: | Reproductive Medicine and Biology |
Subjects: | |
Acceso en liña: | https://doi.org/10.1002/rmb2.12209 |
Títulos similares
-
Medroxyprogesterone Acetate Plus Metformin to Prevent Persistent Endometrial Hyperplasia
por: Vakkas Korkmaz, et al.
Publicado: (2013-08-01) -
Results of surgical treatment of atypical endometrial hyperplasia
por: O. A. Gornykh, et al.
Publicado: (2014-07-01) -
Modern approaches to the diagnosis of endometrial hyperplasia
por: M. M. Damirov, et al.
Publicado: (2025-02-01) -
Microsatellite instability as a reliable marker of coexisting endometrial cancer in atypical endometrial hyperplasia
por: А. E. Protasova, et al.
Publicado: (2024-07-01) -
Endometrial Atypical Hyperplasia and Risk of Endometrial Cancer
por: An-Ju Chou, et al.
Publicado: (2024-11-01)